TY - JOUR
T1 - Proposals for managing patients with thoracic malignancies during COVID-19 pandemic
AU - French Language Society of Pulmonology SPLF French language Oncology Group
AU - Girard, N.
AU - Greillier, L.
AU - Zalcman, G.
AU - Cadranel, J.
AU - Moro-Sibilot, D.
AU - Mazières, J.
AU - Audigier-Valette, C.
AU - Bennouna, J.
AU - Besse, B.
AU - Cortot, A.
AU - Couraud, S.
AU - Duruisseaux, M.
AU - Giroux-Leprieur, E.
AU - Toffart, A. C.
AU - Westeel, V.
AU - Wislez, M.
N1 - Publisher Copyright:
© 2020
PY - 2020/11/1
Y1 - 2020/11/1
N2 - The objective of this document is to formalize a degraded mode management for patients with thoracic cancers in the context of the COVID-19 pandemic. The proposals are based on those of the French High Council for Public Health, on published data outside the context of COVID-19, and on a concerted analysis of the risk-benefit ratio for our patients by a panel of experts specialized on thoracic oncology under the aegis of the French-Language Society of Pulmonology (SPLF)/French-language oncology group. These proposals are evolving (10 April 2020) according to the situations encountered, which will enrich it, and are to be adapted to our institutional organisations and to the evolution of resources during the COVID-19 epidemic. Patients with symptoms and/or COVID-19+ are not discussed in this document and are managed within the framework of specific channels.
AB - The objective of this document is to formalize a degraded mode management for patients with thoracic cancers in the context of the COVID-19 pandemic. The proposals are based on those of the French High Council for Public Health, on published data outside the context of COVID-19, and on a concerted analysis of the risk-benefit ratio for our patients by a panel of experts specialized on thoracic oncology under the aegis of the French-Language Society of Pulmonology (SPLF)/French-language oncology group. These proposals are evolving (10 April 2020) according to the situations encountered, which will enrich it, and are to be adapted to our institutional organisations and to the evolution of resources during the COVID-19 epidemic. Patients with symptoms and/or COVID-19+ are not discussed in this document and are managed within the framework of specific channels.
UR - http://www.scopus.com/inward/record.url?scp=85086571781&partnerID=8YFLogxK
U2 - 10.1016/j.resmer.2020.100769
DO - 10.1016/j.resmer.2020.100769
M3 - Article
C2 - 32563968
AN - SCOPUS:85086571781
SN - 2590-0412
VL - 78
JO - Respiratory Medicine and Research
JF - Respiratory Medicine and Research
M1 - 100769
ER -